HTLV-1 associated myelopathy/tropical spastic paraparesis
Other Names for this Disease
- Human T-cell leukemia virus type 1 associated myelopathy/tropical spastic paraparesis
- Tropical spastic paraparesis (formerly)
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.
On this page
There is no established treatment program for HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). Corticosteroids may relieve some symptoms, but aren’t likely to change the course of the disorder. Clinical studies suggest that interferon alpha provides benefits over short periods and some aspects of disease activity may be improved favorably using interferon beta. Stiff and spastic muscles may be treated with lioresal or tizanidine. Urinary dysfunction may be treated with oxybutynin.
Last updated: 3/16/2011
- Tropical Spastic Paraparesis. National Institute of Neurological Disorders and Stroke. May 9, 2007; http://www.ninds.nih.gov/disorders/tropical_spastic_paraparesis/tropical_spastic_paraparesis.htm. Accessed 3/17/2008.
- ClinicalTrials.gov lists trials that are studying or have studied HTLV-1 associated myelopathy/tropical spastic paraparesis. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.
- The Research Portfolio Online Reporting Tool (RePORT) provides access to reports, data, and analyses of research activities at the National Institutes of Health (NIH), including information on NIH expenditures and the results of NIH-supported research. Although these projects may not conduct studies on humans, you may want to contact the investigators to learn more. To search for studies, enter the disease name in the "Text Search" box. Then click "Submit Query".